Refine your search

Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

467 Study Matches

A Phase 3 Prospective, Randomized, Partially Blinded Multi-Center Study to Measure the Safety and Efficacy of NOVOCART® 3D, Compared to Microfracture in the Treatment of Articular Cartilage Defects.

The purpose of this research study is to assess the pain, stiffness and physical function of the knee in patients with an articular cartilage defect of the knee. Participants will receive one of two possible surgical procedures. One surgical procedure, which is the investigational procedure under study, utilizes the Novocart® 3D autologous cartilage implant system. The other possible procedure is called Microfracture and is one of the current standard of care options to treat this condition. Both surgical procedures will be followed by pain and knee function assessments and a course of physical rehabilitation.
Andrea Horne at ahorne@pennstatehealth.psu.edu or 717-531-7127
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT01957722
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
age 18 to 65
symptomatic knee pain indicative of articular cartilage defects
inadequate response to conservative treatment
Full range of motion of the affected joint
Normally functioning contralateral knee
Exclusion Criteria:
Severe obesity (BMI > 40)
Surgery on the contralateral knee within 6 months prior to the scheduled arthoscopy
intra-articular injections within 1 month of surgery
Prior release and excision of scar tissue except isolated lateral release on target knee
Prior surgical treatment using mosaicplasty, autologous chondrocyte implantation and/or microfracture on target knee (Note: prior debridement and lavage are acceptable if more than three months have passed.)
Sports Medicine, Muscle & Bone
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway–Mutant Acute Lymphoblastic Leukemia

A study of the safety and efficacy of ruxolitinib with routine chemotherapy for children with leukemia with specific genetic changes.
Suzanne Treadway, MS, RN, CCRP at streadway@pennstatehealth.psu.edu or 717-531-3097
All
All
This study is NOT accepting healthy volunteers
NCT02723994
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
A diagnosis of leukemia, specifically de novo high B-ALL with eligible genetic changes.
Age must be greater than 1 year old and less than or equal to 21 years old at leukemia diagnosis.
Have completed an acceptable induction therapy either on study or by hospital standard of care.
Exclusion Criteria:
Had any other chemotherapy before induction therapy, with exceptions.
Down Syndrome.
Children's Health, Cancer
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

The Role of Parental Emotion Regulation in Parent-Child Conflicts

This study seeks to examine parenting skills in responses to child misbehavior. Parents complete rating scales about their child's symptoms and behaviors and also participate in computer tasks to measure brain wave activity through EEG. There is an optional section where parent and child will be video recorded while completing activities together. Following the testing sessions are 8 weeks of counseling sessions for parents to help better manage their child's attention and behavior symptoms.
james waxmonsky at jwaxmonsky@pennstatehealth.psu.edu or 717-531-8646
All
Younger than 18 years old
This study is NOT accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Parent of a child aged 5-12 with ADHD
Child must have mild to moderate symptoms of ODD
Exclusion Criteria:
Not having a child ages 5-12 with ADHD
Non-English speaking
Child with ADHD has diagnosis of mental retardation or prominent traits of autism
No additional child in the family can be enrolled simultaneously in this study
Children's Health, Mental & Behavioral Health
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A phase III, double-blind, randomized placebo-controlled study to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in a genetically defined population with a recent Acute Coronary Syndrome (ACS): The dal-GenE trial

The dal-GenE trial is evaluating the potential of dalcetrapib to reduce cardiovascular morbidity and mortality in patients with a documented recent heart attack or hospitalization due to severe coronary artery disease. Dalcetrapib is an investigational drug (not approved by the United States Food and Drug Administration) that has been evaluated in several large clinical trials, most notably dal-OUTCOMES, a study of over 15,000 patients which was designed to evaluate its effect in patients with recent ACS. The results of this large study demonstrated that treatment with dalcetrapib did not change the risk of cardiovascular disease in the majority of patients with recent ACS. However, after the study was over, researchers identified a group of patients that had a significant benefit. Specifically, the group of patients who had a particular variant (AA) of a gene that all humans share (ADCY9) had their risk of having another cardiovascular event reduced by 39%. Approximately 1 in 5 patients studied had this genetic variant. Those individuals with the AA variant of the will continue in the study and will be started on study drug 4-12 weeks after their index event.
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT02525939
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Male or female age 45 or greater
Admitted to hospital due to blockages in arteries of the heart
Exclusion Criteria:
Bypass surgery to treat your most recent heart event
Severe liver and/or kidney disease
Hemoglobin A1c greater than 10%
Triglyceride level greater than 500mg/dL
Heart & Vascular
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

The Sexual Relationships Study

The purpose of this study is to examine the sexual relationships among heterosexual female college students (ages 18-22) via Qualtrics (a web-based survey). Utilizing latent class analysis with a distal outcome, the proposed cross-sectional study seeks to do the following: Aim 1. Examine the heterogeneity in relationship quality among female college students. Research question 1: Is there a latent class structure that adequately represents the heterogeneity in relationship quality among female undergraduate students participating in penile-vaginal sex? If so, what are the types and their corresponding prevalence? Aim 2. Examine the association between relationship characteristics and latent class membership. Research question 2: Are relationship characteristics (partner type, relationship duration, exclusivity/monogamy, and frequency of sex) predictive of membership in latent classes of relationship quality? Aim 3. Examine the association between latent classes of relationship quality and condom use. Research question 3: Which identified latent class of relationship quality is significantly associated with condom use at last penile-vaginal sex? Please note that the indicators measuring relationship quality will include the following variables: 1) trust, 2) love, 3) passion, 4) commitment, 5) relationship satisfaction, 6) sexual satisfaction, 7) intimacy, and 8) decision-making dominance.
Jessica Salas-Brooks at jis5940@psu.edu or 704-249-4252
Female
18 year(s) or older
This study is NOT accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Be enrolled at Pennsylvania State University (University Park Campus)
Be between the ages of 18-22 years
Be a female college student
Be sexually active with male partners in the previous 3 months
Exclusion Criteria:
Are not enrolled at Pennsylvania State University (University Park Campus)
Are under the age of 18 or over the age of 22.
Are not a female college student
Are not sexually active with male partners in the previous 3 months
Women's Health
  Email this study information to me
  Contact the study team

Improving Autism Screening with Brain-Related miRNA

The central aim of this project is to characterize the expression of exosomal microRNA (miRNA) and nucleic acids in children with autism spectrum disorder (ASD). We propose to measure the expression of extracellular miRNA and nucleic acids in children with ASD. Expression levels of miRNA and nucleic acids from blood and saliva will be compared between children with autism and normally developing controls. The goal of this study will be to identify genetic regulatory mechanisms involved in ASD and provide potential biomarkers for diagnostic screening.
All
Younger than 18 years old
This study is also accepting healthy volunteers
NCT02712853
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Age: 1-4 years
Confirmed Diagnosis of Autism or Developmental Delay or Healthy Child
Exclusion Criteria:
Wards of the state
Sensory Impairment (blindness/deafness)
Confounding neurological condition (cerebral palsy, epilepsy)
Gastrostomy Tube Dependence
Active Peridontal Disease
Children's Health, Mental & Behavioral Health
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Memory and Aging Study

This research is being done to find out more about changes in the brain as we age and to determine if MRI, genetic (DNA) variations, and neuropsychological tests can be used to evaluate memory loss and cognitive impairment.
Lauren Spreen at lspreen@pennstatehealth.psu.edu
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Diagnosis of Alzheimer's disease
Diagnosis of Mild Cognitive Impariment
Normal Controls-Cognitively normal functioning
Exclusion Criteria:
Neurological disease (e.g., stroke, tumor, Parkinson's disease, etc.)
Psychiatric disorder (e.g., bi-polar, schizophrenia, etc.)
History of chemotherapy
Presence of a cold or viral infection
Presence of a pacemaker, aneurysm clips, or any metal in body
Neurology
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Crest-2: Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial

To assess if the proportion of patients with a primary event differs between patients treated with intensive medical management alone compared to CEA, or to CAS, in patients with high grade asymptomatic carotid stenosis. To assess whether intensive medical management differs from CEA and from CAS to maintain the level of cognitive function at 4 years of follow up To assess if there are treatment differences in major stroke, minor stroke, disabling stroke and tissue based stroke at 4 years, using an analytic approach identical to that for the primary aim. To assess if the CEA or CAS versus intensive medical management difference is affected by patient age, sex, severity of carotid stenosis, restenosis, risk factor level and during of the asymptomatic period
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT02089217
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Age >/=35 years
Do you have documented stenosis of your carotid?
Have you had any neurologic symptoms on the same side as your stenosis
No medical history of stroke or TIA on the same side as the stenotic vessel in the previous 180 days
If female, not pregnant
Exclusion Criteria:
Prior stroke with residual disability
Symptomatic ICH within past 12 months
Chronic afib
Ejection fraction < 30%
Do you use an anticoagulant? What medication?
Heart & Vascular, Neurology
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Deprexis Study: An online program to reduce depression in MS – a phase III international multicenter randomized controlled trial

An online program to reduce depression in MS – a phase III international multicenter randomized controlled trial
Deprexis Team Roman at mhc147@psu.edu or 814-865-5578
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT02740361
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Diagnosis of Multiple Sclerosis
Current Depression
No current treatment for depression
Internet access
Between the ages of 18-65
Exclusion Criteria:
No diagnosis of MS
No current psychotherapy for depression
No substantial neurocognitive impairments
Started anti-depressants in the last 2 months
Neurology, Mental & Behavioral Health
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
State College, PA

Tongue movement in adults with motor speech disorder

Tongue movement in adults with motor speech disorder
Jimin Lee at jxl91@psu.edu or 814-863-5338
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
be a native speaker of American English
have normal hearing
between 18 and 40 years of age
have no known speech, language, learning or neurological disorders
have very little experience in communicating with people that have motor speech disorders
Exclusion Criteria:
younger than 18 years of age; older than 40 years of age
Not a speaker of American English only
With hearing impairment
have neurologic and/or speech/language disorders
have extensive experience in communicating with people that have motor speech disorders
Neurology, Muscle & Bone, Language & Linguistics
  Email this study information to me
  Contact the study team
  Show all 2 locations

Study Locations

Hide all locations
Location
Hershey, PA
State College, PA

Exploring Parental Influence in Youth Disability Sport Participation

We are conducting an online survey study for parents of children with disabilities that explores their perceptions of participation in disability sport within their communities.
Courtney Jasiulevicius at cmj5308@psu.edu or 813-846-4145
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
has a child with a physical disability or sensory disability
has a child that is enrolled in a disability or adapted sport program
has a child between the ages of 10 and 17
Exclusion Criteria:
does not have a child with a physical or sensory disability
does not have a child with a disability between the ages of 10 and 17
does not have a child that plays a disability or adapted sport
  Email this study information to me
  Contact the study team

Penn State Hershey Sitting and Health Study

This study aims to examine the effect of pedaling a compact elliptical device at the desk on employees' work productivity. This study also aims to evaluate the effect of different types of incentives on promoting desk-based pedaling.
Liza Rovniak at activitystudy@psu.edu
All
18 year(s) or older
This study is also accepting healthy volunteers
NCT03274635
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Penn State Hershey full time employee
Overweight or obese
Spend at least 5 hours per day sitting at a desk
Have eligible overweight/obese coworker who can do study together with you
18-70 years old
Exclusion Criteria:
Currently pregnant
Planned surgical or medical treatment that will prevent ability to complete study
Heart condition, or chest pain during physical activity
Planned travel or relocation during study period
Already have desk cycling device or treadmill at desk
Heart & Vascular, Prevention, Mental & Behavioral Health
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A Phase I/II Study of Neratinib in Pediatric Patients with Relapsed/ Refractory Solid Tumors

Neratininb for childhood cancer that has returned or is not responding to previous therapy
Suzanne Treadway, MS, RN, CCRP at streadway@pennstatehealth.psu.edu or 717-531-3097
All
All
This study is NOT accepting healthy volunteers
NCT02932280
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Age 3 to 21 Inclusive
Cancer that has returned or is not responding to previous therapy
Has failed at least one prior therapy
Exclusion Criteria:
Certain prior therapies
Children's Health, Cancer
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Women In Steady Exercise Research - Neoadjuvant Exercise Trial

The primary purpose of this pilot study is to determine whether breast cancer patients whom elect to undergo cardiotoxic neoadjuvant chemotherapy can be enrolled and retained in a 6 month at home aerobic exercise training study. Using a randomized controlled trial approach, we will examine the safety and efficacy of a well monitored moderate-to-high intensity aerobic training program completed at home in breast cancer patients receiving neoadjuvant chemotherapy. In addition to assessing safety and efficacy of the program, we will assess intervention effects on cardiopulmonary fitness, cardiac function, and tumor response.
Kathleen Sturgeon at kms99@psu.edu or 717-531-0003, ext=284676
Female
18 year(s) or older
This study is NOT accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Stage 1-3 breast cancer
Scheduled to start neoadjuvant chemotherapy
Sedentary
No heart disease
Exclusion Criteria:
Stage 4 breast cancer
Heart disease
Non-English speaking
Cancer
  Email this study information to me
  Contact the study team
  Show all 3 locations

Study Locations

Hide all locations
Location
Greater Philadelphia Area, PA
Harrisburg, PA
Hershey, PA

Aging and Language

The purpose of this study is to investigate how language is organized in neurologically normal adults using magnetic resonance imaging (MRI) and behavioral measures. Our overarching goal is to characterize the behavioral and MRI responses associated with language production and language comprehension in older and younger adults, and to examine the relations between age, behavior, cognition, and neural factors.
Michele Diaz at mtd143@psu.edu or 814-863-1726
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Age over 18 years old
Native Monolingual English Speaker
Right-handed
Exclusion Criteria:
History of neurological injury or disease
Taking medications that affect the brain of blood flow
Contraindications to MRI (e.g., pacemaker)
Claustrophobia
Language & Linguistics
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
State College, PA

Interoception, the 8th Sensory System, Is it measurable?

Sensory processing is often affected in children and adolescents with ASD (autism). The 8th sensory system, coined interoception, is under studied in how it affects children with autism. Our study will compare children with and without autism (ages 11-18 years) using a tool we are developing. Our study hopes to develop psychometric properties of a tool to measure this new sensory sense.
Cheryl Tierney at ctierney@pennstatehealth.psu.edu or 717-531-8414
All
All
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Ages 11-18
Reading at 5th grade level in English
Healthy controls OR high functioning Autism
Exclusion Criteria:
Unable to read at 5th grade reading level
Under age 11 or over age 18
Cannot read English
Children's Health, Mental & Behavioral Health
  Email this study information to me
  Contact the study team

Prediction of Muscle Force Generation using Ultrasound Imaging and Computational Simulations

The objective of this study is to develop and validate a method to predict force production of individual muscles from ultrasound measurements of muscle stiffness, size, and structure. We will place acupuncture needles to the muscles and applied a small amount of current to induce contraction. Force and ultrasound measurements will be performed during muscle contraction. This process will be done in three muscles, one in the arm and two in the leg.
Daniel Cortes at researchsubjects@mne.psu.edu or 814-863-3103
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Healthy individuals without history of muscle disease or injury
Exclusion Criteria:
Pregnant women
Allergy to ultrasound gels
contraindications to MRI scans
Muscle & Bone
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
State College, PA

Study driver situation awareness and behavior in connected and autonomous vehicles with a driving simulator

This is a behavioral study that will examine the effect of different message designs and driver characteristics on driver situation awareness and driving behavior in connected and autonomous vehicles. The driving simulator will be used to simulate various traffic events in connected and autonomous vehicle environments. All you need to do is driving on a driving simulator or watch driving scenarios online and complete questionnaires.
Xiaomei Tan at xzt24@psu.edu
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
You must possess a valid and unrestricted driver’s license for at least two years, and display it to the experimenter
You must not be under the influence of alcohol, and have abstained from drinking alcohol for no less than 8 hours prior to participating in this study
You must have normal vision or correct vision.
Exclusion Criteria:
Participants who doesn't possess a valid driver license will be excluded from the study
Participants who drinks alcohol within the 8 hours before the study will be excluded from the study
Education, Mental & Behavioral Health, Language & Linguistics
  Email this study information to me
  Contact the study team

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of CC-220 in Subjects with Active Systemic Lupus Erythematosus

This study is for patients with SLE (systemic lupus erythematosus) to determine the effectiveness and safety of drug CC-220 on improving SLE and to see how well the body tolerates the medication.
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03161483
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Diagnosis of Systemic Lupus Erythematosus
Exclusion Criteria:
Diagnosis of Fibromyalgia
Active or history of recurrent bacterial, viral or fungal infections
History of latent or active tuberculosis
History of blood clots in the past year
Infectious Diseases & Immune System, Arthritis & Rheumatic Diseases, Muscle & Bone
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Role of microRNA activation of lectin-like oxidized LDL receptor (LOX-1) mechanisms in microvascular dysfunction in women with endometriosis

Endometriosis is a gynecological disorder associated with chronic pelvic pain, pain during intercourse, and infertility. With endometriosis, endometrium-like tissue is found in sites outside the uterine cavity. This disorder affects 6% - 10% of women of reproductive age. It can be as high as 35-50% in women who have pain or infertility. Endometriosis is associated with higher risk of hypercholesterolemia and hypertension that increases risk for cardiovascular disease (CVD). CVD is characterized by dysfunction of the blood vessels of the body. CVD is the leading cause of death in women. Two groups of women complete this study: 1) healthy women between the ages of 18 and 45 years (Controls); 2) women between the ages of 18 and 45 years with endometriosis. The screening and two experiments include blood draws. After passing a medical screening, each subject participates in a microdialysis (MD) experiment before and after 6-9 days of oral atorvastatin therapy (10mg/day). Atorvastatin (brand name: Lipitor) is an FDA-approved drug that physicians prescribe to lower blood cholesterol. The atorvastatin also suppresses substances made by the body that increase the risk of CVD. MD is a procedure in which a thin tube of membrane that mimics a capillary blood vessel is implanted in the skin. Substances of interest are added to the saline flowing through the MD sites and are delivered into small areas of skin. The MD experiments combine the perfusion of the test-substances with local heating of the skin to explore the causes for the dysfunction of blood vessels and increased risk for CVD that occurs with endometriosis.
Susan Slimak at sks31@psu.edu or 814-863-8556
Female
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Women, Ages 18-45
Do or do not have endometriosis
Have normal blood pressure
Exclusion Criteria:
Use of nicotine-containing products (e.g. smoking, chewing tobacco, etc.)
High Blood Pressure
Abnormal liver function
Known allergy statins (Lipitor)
Pregnant or Breastfeeding
Pregnancy & Infertility, Women's Health, Heart & Vascular
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
State College, PA

Invisible Sojourners: Second Language Socialization Among International Spouses

This study will examine how international spouses improve their English ability and form connections with the local community. Participants will be interviewed to learn about their experiences. Social events that are found to be positive will be recorded so that the interactions in that space can be analyzed to determine how they help international spouses.
Jade Sandbulte at jfs5644@psu.edu
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Traveled to the U.S. with a spouse who was enrolled at Penn State
Understands spoken English
Exclusion Criteria:
Is not a student at Penn State OR was not a student when you first arrived
Education, Language & Linguistics
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
State College, PA

Investigation of Semantic Processing in Context

The purpose of this study is to investigate the effects of context on the processing of words in young adults with and without an autism spectrum disorder. The knowledge gained may lead to further understanding of the cognitive and linguistic processing of individuals with autism spectrum disorder—how they understand and see the world around them. The study is being conducted at our on-campus lab and includes the completion of some standardized paper and pencil tests and some computer-based activities. Participants receive compensation for their participation.
DIANE WILLIAMS at dlw81@psu.edu or 814-865-3177
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Speak English as primary language
Normal or corrected to normal vision
Normal hearing
With or without a diagnosis of an autism spectrum disorder or Asperger syndrome
Exclusion Criteria:
Cannot speak sentence length English
Vision problems (uncorrected)
Hearing problems
Mental & Behavioral Health, Language & Linguistics
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
State College, PA

Reducing Perception Error in Diagnostic Radiology

This research is being done to find out the relationship between an individual’s mental state and how well they perform visual-perceptual tasks. This will allow us to understand the brain processes related to errors in image perception, to understand how mental states impact medical image interpretation. Overall, this research will help us develop training programs to reduce the amount of perceptual errors in diagnosing images
Lauren Spreen at lspreen@pennstatehealth.psu.edu or 717-531-5857
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Radiologists with different levels of experience
Healthy adults, with college or advanced degree
Normal or corrected to normal vision
Exclusion Criteria:
Non-English speaking
Pregnant or lactating
Presence of pacemaker, aneurysm clips, or any metal in the body
A history of welding or grinding
Claustraphobia
Education
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Single Arm Phase Ib/II Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer: Big Ten Cancer Research Consortium (BTCRC-GU16-043) (PSCI 18-008)

This study is being done to test the safety of combining durvalumab with guadecitabine. It will also measure the percentage of patients whose tumor shrank after receiving durvalumab in combination with guadecitabine. Participants with kidney cancer that has spread to other parts of the body, also known as 'metastatic kidney cancer' will be recruited to participate.
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03308396
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Histological diagnosis of clear cell renal cell carcinoma (pure or mixed) with radiologic or histologic evidence of metastatic disease
Prior cancer treatment must be completed at least 14 dats prior to study registration and the subject must have recovered from all reversible acute toxic effects of the regimen (other than alopecia) to Grade 1 or less baseline
ECOG Performance Status 0-1 within 28 days prior to registration
Demonstrate adequate organ function based on necessary screening labs to be obtained within 28 days prior to registration
Females of childbearing potential must have a negative serum pregnancy test within 28 days prior to registration
Exclusion Criteria:
Active infection requiring systemic therapy
Brain metastases or spinal cord compression
Pregnant or breastfeeding
Treatment with any investigational drug within 14 days prior to study registration
Current or prior use of immunosuppresive medication within 28 days before the first dose of durvalumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiologic doses
Kidney & Urinary System, Cancer
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Asymmetric neurodegeneration of central olfactory system in early-stage Parkinson’s disease

This research is being done to study the deterioration of the central olfactory system (sense of smell system) in the brains of patients diagnosed with H&amp;Y stage 1 or 2 Parkinson’s disease compared to that of healthy volunteers.
Lauren Spreen at lspreen@pennstatehealth.psu.edu or 717-531-5857
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Cognitively-normal H&Y stage 1 PD patients. A physician-documented parkinsonian symptom onset between the ages of 40-59. 1st visit prior to age 65. PD stage I diagnosis must be documented for a min of 2 years.
Cognitively-normal H&Y stage 2 PD patients. H&Y stage 2, as defined by an exam in the practically defined “off” state, and have a diagnosis of PD at the age of 59 or younger. 1st visit prior to age 65
Healthy participants between ages 40-64 at their first visit.
Able and willing to provide informed consent
Fluent in written and spoken English
Exclusion Criteria:
Parkinson-plus syndrome
Dementia
Previous antipsychotic or anti-dopamine drug therapy
Traumatic head injury
Other neurological diseases or disorders
Neurology
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Site For COMET-PCOS

Site For COMET-PCOS
Patsy Rawa at prawa@pennstatehealth.psu.edu or 717-531-3692
Female
18 year(s) or older
This study is also accepting healthy volunteers
NCT03229057
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Polycystic ovary syndrome (PCOS)
BMI >=25 to <=45
In good general health
Willing to avoid pregnancy for duration of study
Exclusion Criteria:
Currently pregnant or desire of pregnancy
Currently breastfeeding
Untreated thyroid disease
Untreated hyperprolactinemia
Type 1 or Type 2 diabetes
Women's Health
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Site For AbbVie- HS Surgery

Site For AbbVie- HS Surgery
Logan Claar at lclaar@pennstatehealth.psu.edu or 717-531-5136
All
18 year(s) or older
This study is NOT accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Must be able to travel to Hershey Medical Center for 12 visits
Must be diagnosed with HS for 1 year prior to study participation
Must be willing to perform self injections at home
Exclusion Criteria:
Prior treatment of Humira or other biologics for the treatment of HS
Skin Conditions
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Site For 18-047, EA9152 Venetoclax (ABT-199) in Combination with Liposomal Vincristine in Patients with Relapsed or Refractory T-cell or B-cell ALL

Site For 18-047, EA9152 Venetoclax (ABT-199) in Combination with Liposomal Vincristine in Patients with Relapsed or Refractory T-cell or B-cell ALL
Lea Russell at PSCI-CTO@pennstatehealth.psu.edu or 717-531-5471
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03504644
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Relapsed or refractory B-cell or T-cell ALL after multi-agent chemotherapy(≥ 5% marrow lymphoblasts, assessed by morphology and flow cytometry
ECOG performance status 0-2
Creatinine clearance of at least 50 mL/min within 7 days prior to first dose of study agent
Adequate liver function with AST/ALT less than 3X upper limit of normal and total bilirubin less than 2 mg/dL within 7 days prior to first dose of study agent
Circulating WBC count must not be above 20 x10^9/L within 7 days prior to first dose of study agent
Exclusion Criteria:
Pregnant or breast-feeding due to risk of fetal harm by the chemotherapeutic agents prescribed in this protocol
Evidence of isolated extramedullary relapse (i.e., testicular or CNS)
Serious medical or psychiatric illness that in the opinion of the primary investigator is likely to interfere with study participation may not be enrolled
Poorly controlled HIV, or CD4 < 400. HIV positive patients are allowed on this study if they have a CD4 count greater than or equal to 400, and are on a stable antiviral regimen
Patients with NYHA Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia may not be enrolled
Cancer
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Biological Activity, and PK of ND-L02-s0201 in Subjects with Idiopathic Pulmonary Fibrosis (IPF)

This study is for patients 40-80 years of age with IPF (idiopathic pulmonary fibrosis). This study is being done to learn more about an experimental medication which is being developed to treat fibrosis or scarring of the lungs. The purpose of this study is to evaluate the safety of this experimental medication when administered at two dose levels compared with placebo (injection containing no active medication).
Donna Griffiths at dgriffiths@pennstatehealth.psu.edu or 717-531-5519
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03538301
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Must be 40-80 years of age
Have a diagnosis of IPF within the past 5 years
Unchanged dose of pirfenidone or nintedanib for at least 12 weeks if currently taking these medications
Exclusion Criteria:
Respiratory exacerbation or hospitalization in the last 3 months
Taking both pirfenidone and nintedanib simultaneously in the past 12 weeks
Lung transplant anticipated during the study
Known history of liver cirrhosis
Active smoker or cessation in the past 12 weeks
Lung Disease & Asthma
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema following Large Hemispheric Infarction

This is a Phase 3 study, which means that BIIB093 (study drug) has already been investigated in previous clinical research studies with a small number of people with large hemispheric infarction (LHI). These studies suggested that the study drug was safe, did not cause serious side effects or discomfort, and may reduce brain swelling, disability, and death in subjects with LHI. In this study, we want to investigate the study drug in a larger number of subjects (hundreds) to know more about it. LHI is a type of stroke. An ischemic stroke occurs when blood flow to parts of the brain is blocked, such as by a blood clot. This can cause damage to the brain. In LHI a large portion of the brain is damaged. People who have LHI can develop swelling of the brain called cerebral edema, which can worsen the symptoms and outcomes of LHI. Currently, there are no medications available to specifically reduce brain swelling caused by LHI. In this study, we want to investigate how well the study drug works to improve functional outcomes (the ability to do normal daily activities, such as walking and getting dressed) in subjects with LHI. This study will also look at the long-term effects of the study drug over time and see how safe the study drug is.
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT02864953
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
A clinical diagnosis of acute ischemic stroke in the MCA territory within 10 hours of symptom onset
Aged 18 to 85 years old, inclusive, at the time of informed consent
Screening NIHSS ≥10
Exclusion Criteria:
In the judgment of the Investigator, the subject is likely to have supportive care withdrawn in the first day
Commitment to decompressive craniectomy (DC) prior to enrollment
Evidence (clinical or imaging) of concurrent infarction in the contralateral hemisphere deemed by the Investigator to be sufficiently serious so as to affect functional outcome
Clinical signs of herniation and/or loss of other brain stem reflexes, attributable to edema or herniation according to the Investigator’s judgment
Brain hemorrhage (other than small petechial/punctate hemorrhages) on NCCT/MRI
Neurology
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA